Mirum Pharmaceuticals shares are trading higher after the company announced interim results from two Phase 2b studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis.
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals shares are trading higher following the announcement of positive interim results from two Phase 2b studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis.
June 17, 2024 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirum Pharmaceuticals shares are trading higher due to positive interim results from two Phase 2b studies on volixibat for treating primary biliary cholangitis and primary sclerosing cholangitis.
The positive interim results from the Phase 2b studies are likely to boost investor confidence in Mirum Pharmaceuticals' pipeline, leading to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100